XERIS BIOPHARMA HOLDINGS, INC. (XERS) Total liabilities 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) total liabilities at each fiscal year-end, per SEC filings.
$369.8MFY2025 · since FY2020: $125.4M → $369.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $369.8M | +4.9% |
| FY2024 | $352.7M | +7.1% |
| FY2023 | $329.4M | +10.0% |
| FY2022 | $299.3M | +43.1% |
| FY2021 | $209.1M | +66.8% |
| FY2020 | $125.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating marginXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Shareholders’ equityXERS overview →